IVDT_In Vitro Diagnostics Technology

IVD Technology, November/December 2012

Issue link: http://dc.cn.ubm-us.com/i/92152

Contents of this Issue

Navigation

Page 26 of 43

ers are focused on individual results. To properly diagnose and manage this type of patient, the clinician would need to page through mul- tiple results, mentally build a trend, and have the patient supply context. Genes sug- gests that patients who buy an over-the-counter cholesterol test will need signifi cantly more counseling in how to interpret results, a service pharmacies may perhaps step in to provide. "Moreover," he says, "as devices proliferate, data displays also will need to be simpli- fi ed and standardized, so patients and clinicians can grasp the signifi cance of the data at a glance." One cannot establish baselines or perform regression analysis without multiple points. It is true that with EMRs, data from multiple tests are stored, and it is possible to page from one record to another looking at the PST POL PCS PST PCS No. of devices POL - Physician Office Lab PCS - Patient-Collected Sample PST - Patient Self-Testing POL Time to result Figure 1. Cost versus distribution and frequency versus time to result. change in any metric. But consumer- driven tools worn or used by patients produce signifi cantly more intra-exam information, establish trends, engage the patient, and enable personalized interventions. In a TedMED pre- sentation, Leslie Saxon, MD, at the USC School of Medicine and Center for Body Computing, cites more than 150,000 potential therapeutic interventions from implanted devices Pharmaceutical brand managers privately admit that the area they have the least access to but want the most control over is that moment between the diagnosis and the thera- peutic decision. If they were present in the exam room and on the iPad, it would make a diff erence not only in prescription volumes, but also in med- ication adherence. Diagnostics could be the vehicle for providing a patient service that educates and involves the patient in his or her care, improving adherence and outcomes as well as prescriber confi dence. wirelessly transmitting data.4 Saxon recounts how, while reviewing incoming ECGs from patients transmit- ting them remotely via their mobile phones, she was able to notify a patient in Mumbai that he was about to experi- ence an impending heart attack. Monoclonal & Polyclonal Antibodies, Proteins, ELISA Kits, Specialty Research Products and Matched Pair Components Infectious Diseases Chlamydia Hepatitis HIV & SIV Influenza A/B M tuberculosis Respiratory Syncytial Virus Rotavirus Streptococcus Hormones & Steroids C-Peptide Estradiol Estriol FSH HCG Insulin LH Prolactin Testosterone Thyroglobulin TSH beta/alpha Tumor Markers CA 15-3 CA 19-9 CA 27-29 CA 50 CA 72-4 CA 125 AFP b2 microglobulin CEA Cyfra 21-1 PSA PAP Cardiac Markers Apo (a) CKMB CKMM CRP D-Dimer FABP Myeloperoxidase Myoglobin Troponin I-T-C Adrenal & Pancreatic Drugs of Abuse/TDM Fertility & Pregnancy Thyroid Diseases Animal Serum & Red Blood Cells HAMA Blocking Reagents Poly-HRP 20/40/80 Fitzgerald Industries International T 800.370.2222 or 978.371.6446 F 978.371.2266 E antibodies@fitzgerald-fii.com ivdtechnology.com www.fitzgerald-fii.com IVD TECHNOLOGY | NOVEMBER/DECEMBER 2012 27 Cost per test Test frequency

Articles in this issue

Links on this page

Archives of this issue

view archives of IVDT_In Vitro Diagnostics Technology - IVD Technology, November/December 2012